

- 2 Corporation). Light emission is measured with a luminometer (Berthold) for a
period of 5 seconds. The data is reported in relative light units per second per
4 *tibialis anterior*.

Samples	RLU/s per 1 x 10 ⁶ cells
DC isolated from muscles injected with CMV-Luc in saline	272±50
DC isolated from muscles injected with pCMV-Luc formulated with PLURONIC F127/PLURONIC L61 @0.01 w/v	3155±360

6 There will be various modifications, improvements, and applications of the
disclosed invention that will be apparent to those of skill in the art, and the present
8 application is intended to cover such embodiments. Although the present
invention has been described in the context of certain preferred embodiments, it is
10 intended that the full scope of these be measured by reference to the scope of the
following claims.

12 The disclosures of various publications, patents and patent applications that
are cited herein are incorporated by reference in their entireties.

WHAT IS CLAIMED IS:

- 16 1. Composition for inducing activation of dendritic cells comprising a
polynucleotide, viral vector, or polynucleotide derivative thereof and at
18 least one polyoxyethylene-polyoxypropylene block copolymer.
- 20 2. The composition of claim 1 further comprising a polycation.
- 22 3. The composition of claim 2 wherein the polycation is a polyamine polymer.

- 2 4. The composition of claim 2 wherein the polycation is an oligoamine or an
oligoamine conjugate.
- 4
- 6 5. The composition of claim 1 wherein there is a mixture of block copolymers.
- 8 6. The composition of claim 5 wherein the block copolymers comprise a
mixture wherein at least one block copolymer with oxyethylene content of
50% or less, and at least one block copolymer with oxyethylene content of
10 50% or more.
- 12 7. The composition of claim 5 6 wherein the block copolymers comprise a
mixture a first block copolymer component having an oxyethylene content
14 of 50% or less, and a second block copolymer component having an
oxyethylene content of 50% or more wherein the weight ratio of said
16 second block copolymer to said first block copolymer is at least 2:1.
- 18 8. The composition of claim 6 wherein the block copolymers comprise a
mixture a first block copolymer component having an oxyethylene content
20 of 50% or less, and a second block copolymer component having an
oxyethylene content of 50% or more wherein the weight ratio of said
22 second block copolymer to said first block copolymer is at least 5:1.
- 24 9. The composition of claim 5 wherein the copolymers comprise a mixture
wherein at least one block copolymer has an oxyethylene content of 70%
26 or more and at least one block copolymer has an oxyethylene content of
50% or less.
- 28
- 30 10. The composition of claim 5 wherein N, according to the following
expression, is from about 0.2 to about 9.0 and preferably from about 0.25
to about 1.5:

2

$$N = 1.32 \cdot \left[\frac{H_1 \cdot m_1}{(L_1) \cdot (m_1 + m_2)} + \frac{H_2 \cdot m_2}{(L_2) \cdot (m_1 + m_2)} \right]$$

4

in which H_1 and H_2 are the number of oxypropylene units in the first and second block copolymers, respectively; L_1 is the number of oxyethylene units in the first block copolymer; L_2 is the number of oxyethylene units in the second block copolymer; m_1 is the weight proportion in the first block-copolymer; and m_2 is the weight proportion in the second block copolymer.

6

8




10



11. The composition of claim 5 wherein the mixture comprises the block copolymer PLURONIC® F127.

12

12. The composition of claim 1, wherein at least one of the block copolymers has the formula:



14





in which x , y , z , i , and j have values from about 2 to about 400, and wherein for each R^1 , R^2 pair, one is hydrogen and the other is a methyl group.

13. The composition of claim 1 wherein at least one of the block copolymers has the formula:



in which x , y , z , i , and j have values from about 2 to about 400, and for each R^1 , R^2 pair, one is hydrogen and the other is a methyl group.

14. The composition of claim 1 wherein the block copolymer comprises at least PLURONIC F127 and L61.

15. The composition of claim 14 wherein the ratio of PLURONIC F127:L61 is 8:1.

16. The composition of claim 14 wherein PLURONIC F127 is in the amount of about 2%w/v and PLURONIC L61 is in the amount of about 0.025% w/v.

17. The composition of claim 1 wherein said block copolymer is present in amounts insufficient for gel formation.

18. A composition for inducing the activation of dendritic cells comprising a polynucleotide or derivative thereof and at least one polyoxyethylene-polyoxypropylene block copolymer, wherein the block copolymer is present at a concentration below about 15% wt/vol.

19. The composition of claim 18 wherein the block copolymer concentration is below about 10%.

20. The composition of claim 18 wherein the block copolymer concentration is below about 5%.

21. A composition for inducing the activation of dendritic cells comprising a polynucleotide or derivative thereof and at least one polyoxyethylene-

2 polyoxypropylene block copolymer, wherein the composition forms a
molecular solution or colloidal dispersion.

4

22. The composition of claim 21 wherein the colloidal dispersion is a
6 suspension, emulsion, microemulsion, micelle, polymer complex, or other
type of molecular aggregate.

8

23. The composition of claim 21 wherein the colloidal dispersion comprises
10 molecular species that are less than about 300 nm.

12 24. The composition of claim 21 wherein the colloidal dispersion comprises
molecular species that are less than about 100 nm.

14

25. The composition of claim 21 wherein the colloidal dispersion comprises
16 molecular species that are less than about 50 nm.

18 26. The composition of claim 1 wherein the polynucleotide is RNA, DNA,
plasmid DNA, virus, or viral vector.

20

27. The composition of claim 1 wherein the polynucleotide encodes a secreted
22 or non-secreted protein, vaccine or antigen.

24 28. The composition of claim 1 comprising a gene expressing a secreted or
non-secreted protein, vaccine or antigen and at least one gene expressing
26 an adjuvant molecule operable to activate antigen presenting cells and
induce immune response for enhanced antigen presentation.

28

29. A method of inducing activation of dendritic cells comprising administering
30 a composition comprising a polynucleotide or derivative thereof and at
least one polyoxyethylene-polyoxypropylene block copolymer.

- 2
30. The method of claim 30 wherein the block copolymers comprise at least
- 4 PLURONIC F127 and L61.
- 6
31. The method of claim 30 wherein the block copolymer is present in amounts
- 8 insufficient for gel formation.
- 10
32. A method of inducing activation of dendritic cells comprising administering a
- 12 composition comprising a polynucleotide or derivative thereof and at least
- one polyoxyethylene-polyoxypropylene block copolymer, wherein the
- composition forms a molecular solution or colloidal dispersion.
- 14
33. The method of claim 32 wherein the block copolymers are PLURONIC
- 16 F127 and L61.
- 18
34. A method of increasing the immune response of an animal comprising
- administering the composition according to claim 1.
- 20
35. The method of claim 34 wherein the block copolymers comprise at least
- 22 PLURONIC F127 and L61.
- 24
36. The method of claim 34 wherein the composition is administered orally,
- topically, rectally, vaginally, parenterally, intramuscularly, intradermally,
- subcutaneously, intraperitoneally, or intravenously.
- 26
37. A method of increasing the immune response of an animal comprising
- 28 intramuscularly administering the composition according to claim 1.
- 30
38. The method of claim 37 wherein the block copolymers comprise at least
- PLURONIC F127 and L61.

2 39. The method of claim 37 wherein said composition is administered to at
least one of smooth, skeletal, and cardiac muscles.

4 40. A method of increasing the immune response of an animal comprising
6 intradermally administering the composition according to claim 1.

8 41. A composition for inducing the activation of dendritic cells comprising at least
one polyoxyethylene-polyoxypropylene block copolymer.

10 42. The composition of claim 41 further comprising a polycation.

12 43. The composition of claim 42 wherein the polycation is a polyamine polymer.

14 44. The composition of claim 41 wherein the polycation is an oligoamine or an
16 oligoamine conjugate.

18 45. The composition of claim 41 wherein there is a mixture of block
copolymers.

20 46. The composition of claim 45 wherein the block copolymers comprise a
22 mixture wherein at least one block copolymer with oxyethylene content of
50% or less, and at least one block copolymer with oxyethylene content of
24 50% or more.

26 47. The composition of claim 46 wherein the ratio by weight of the block
copolymer with oxyethylene content of 50% or less to the block copolymer
28 with oxyethylene content of 50% or more is 1:2.

48. The composition of claim 46 wherein the ratio by weight of the block copolymer with oxyethylene content of 50% or less to the block copolymer with oxyethylene content of 50% or more is 1:5.

49. The composition of claim 45 wherein the copolymers comprise a mixture wherein at least one block copolymer with oxyethylene content of 70% or more and at least one block copolymer with oxyethylene content of 50% or less.




50. The composition of claim 45 wherein N, according to the following expression, is from about 0.2 to about 9.0 and preferably from about 0.25 to about 1.5:

$$N = 1.32 \cdot \left[\frac{H_1 \cdot m_1}{(L_1) \cdot (m_1 + m_2)} + \frac{H_2 \cdot m_2}{(L_2) \cdot (m_1 + m_2)} \right]$$



in which H_1 and H_2 are the number of oxypropylene units in the first and second block copolymers, respectively; L_1 is the number of oxyethylene units in the first block copolymer; L_2 is the number of oxyethylene units in the second block copolymer; m_1 is the weight proportion in the first block-copolymer; and m_2 is the weight proportion in the second block copolymer.

51. The composition of claim 45 wherein the mixture comprises the block copolymer PLURONIC® F127.

52. The composition of claim 41, wherein at least one of the block copolymers has the formula:





2



4 in which x , y , z , i , and j have values from about 2 to about 400, and
 6 wherein for each R^1 , R^2 pair, one is hydrogen and the other is a methyl
 group.

8 53. The composition of claim 41 wherein at least one of the block copolymers
 has the formula:



in which x , y , z , i , and j have values from about 2 to about 400, and for each R^1 , R^2 pair, one is hydrogen and the other is a methyl group.

54. The composition of claim 41 wherein the block copolymer comprises at least PLURONIC F127 and L61.

55. The composition of claim 40 wherein the block copolymer is present in amounts insufficient for gel formation.

56. A composition for inducing the activation of dendritic cells comprising at least one polyoxyethylene-polyoxypropylene block copolymer, wherein the composition forms a molecular solution or colloidal dispersion.

57. The composition of claim 56 wherein the colloidal dispersion is a suspension, emulsion, microemulsion, micelle, polymer complex, or other type of molecular aggregate.

58. The composition of claim 56 wherein the colloidal dispersion comprises molecular species that are less than about 300 nm.

59. The composition of claim 56 wherein the colloidal dispersion comprises molecular species that are less than about 100 nm.


60. The composition of claim 56 wherein the colloidal dispersion comprises molecular species that are less than about 50 nm.

61. A composition for inducing activation of dendritic cells comprising a polynucleotide or derivative thereof and at least one polycationic polymer having a plurality of cationic repeating units.

62. A polynucleotide composition according to Claim 61 wherein said polycationic polymer is a cationic homopolymer, copolymer or block copolymer comprising one or more of the following fragments:


(a) at least one aminoalkylene monomer selected from a group consisting of:

(i) a tertiary amine monomer of the formula



and,

(ii) a secondary amine monomer of the formula



in which:

each of R^1 , R^4 , R^5 , R^6 and R^8 taken independently of each other is hydrogen, alkyl of 2 to 8 carbon atoms, another A monomer, or another B monomer;

each of R^2 , R^3 and R^7 , taken independently of each other, is a straight or branched alkanediyl of the formula $-(C_zH_{2z})-$ wherein z has a value of from 2 to 8;

(b) cationic amino acids;

(c) $(-OPO(NH-R^9-NR^{10}R^{11}R^{12})O-R^8-)$ in which R^9 is a stright chain aliphatic group of from 1-12 carbon atoms and R^8 is $-(CH_2)_n-CH(R^{13})-$ where n is an integer from 0 to 5, R^{10} , R^{11} and R^{12} are independently hydrogen or alkyl of 1 to 4 carbon atoms and R^{13} is a hydrogen, cycloalkyl having 3-8 carbon atoms. or alkyl of 1-2 carbon atoms; and
(d) vinylpyridine or a derivative thereof.

63. A composition according to claim 62 comprising a polynucleotide and a polymer of a plurality of segments, wherein the polymers comprise at least one polycationic segment which is cationic homopolymer, copolymer, or block copolymer, or quaternary salt thereof; and either,

(a) at least one straight or branched chain polyether segment of from 5 to about 400 monomer units which polyether segment is:

(i) a homopolymer of at least one alkyleneoxy monomer $-OC_nH_{2n}-$ in which n has a value from 2 to 3; or,

(ii) a copolymer or block copolymer of said first alkyleneoxy monomer and a second different alkyleneoxy monomer $-OC_mH_{2m}-$, in which n has a value from 2 to 3 and m has a value from 2 to 4 or,

(b) a homopolymer or copolymer of at least one monomer from a group consisting of acrylamide, glycerol, vinyl alcohol, vinyl pyrrolidine,

2 vinylpyridine-N-oxide, oxazoline, morpholine acrylamide, and derivatives
thereof.

4
64. A composition according to claim 63 wherein said first alkyleneoxy
6 monomer is ethyleneoxy (-OCH₂CH₂-) and said second alkyleneoxy
monomer is propyleneoxy (-OCH(CH₃)CH₂-).

8
65. A composition of claim 63 wherein the polycationic polymer, at
10 physiological pH, comprise at least six cationic groups.

12
66. A polynucleotide composition according to claim 63 wherein the
polycationic polymer, at physiological pH, contain a plurality of cationic
14 groups separated by about 3Å to about 12Å.

16
67. A polynucleotide composition according to claim 63 wherein each of
said polyether segments has from about 5 to about 80 monomeric units
18 and said polycationic segment is a homopolymer, copolymer or block
copolymer of from 2 to about 180 of the same or different monomeric
20 units of the formula -NH-R^o- in which R^o is a straight chain aliphatic
group of 2 to 6 carbon atoms which may be optionally substituted.

22
68. A composition according to claim 69 wherein the polycationic polymer is
24 covalently linked with at least one nonionic polymer segment.

26
69. A method of inducing activation of dendritic cells comprising administering
a composition comprising a polynucleotide or derivative thereof and at
28 least one polyoxyethylene-polyoxypropylene block copolymer.

30
70. A method of inducing the activation of dendritic cells comprising
administering a composition comprising at least one polyoxyethylene-

polyoxypropylene block copolymer, wherein the block copolymer is present in amounts insufficient for gel formation.

71. The method of claim 70 wherein the block copolymers comprise at least PLURONIC F127 and L61.

72. A method of inducing activation of dendritic cells comprising administering a composition comprising at least one polyoxyethylene-polyoxypropylene block copolymer, wherein the composition forms a molecular solution or colloidal dispersion.

73. The method of claim 72 wherein the block copolymers are PLURONIC F127 and L61.

74. A method of increasing the immune response of an animal comprising administering the composition according to claim 72.

75. The method of claim 72 wherein the composition is administered orally, topically, rectally, vaginally, parenterally, intramuscularly, intradermally, subcutaneously, intraperitoneally, or intravenously.

76. The method of claim 72 wherein said composition is administered to at least one of smooth, skeletal, and cardiac muscles.

77. A method of improving the immune response of an animal comprising intradermally administering the composition according to claim 34.